MedTrace Logo

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

NCT03319316 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-01-10

No results posted yet for this study

Summary

This is a multicenter, 2-arm open-label, randomized comparative phase II study in each of two separate cohorts (non-squamous NSCLC and squamous NSCLC) according to histology.

Conditions

  • Squamous Non-small Cell Lung Cancer
  • Non-Squamous Non-small Cell Lung Cancer

Interventions

DRUG

Durvalumab

Combination of durvalumab + tremelimumab treatment

DRUG

Tremelimumab

Combination of durvalumab + tremelimumab treatment

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Martin Reck, Pr · Lungen Clinic Grosshansdorf, Grosshansdorf, Germany

  • Lizza Hendriks, MD · Academisch Ziekenhuis Maastricht, The Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2021-11-30
Completion
2022-11-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03319316 on ClinicalTrials.gov